This abstract presents an economic assessment of hypothermic oxygenated perfusion (HOPE) for liver transplantation in the US, using interim data from a randomized trial, Bridge to HOPE, comparing static cold storage (SCS) with and without HOPE for DBD and DCD donor grafts. HOPE significantly reduced complications-including biliary complications, graft failure requiring retransplantation, and initial hospital length of stay-leading to a cost savings of over $21,000 per case compared to SCS alone based on initial 6-month outcomes. Sensitivity analyses confirmed robust financial benefits, especially in transplants from extended criteria donors, suggesting HOPE may increase hospital revenue and transplantation capacity by reducing postoperative complications and hospitalization time.
Axelrod D, Reich D, Schnitzler M. Economic Assessment Of Hypothermic Oxygenated Machine Perfusion In Liver Transplantation: Interim Analysis. Presented at: American Transplant Congress; June 2-5, 2024; Philadelphia, PA
